PLx Pharma Inc. to Present at Biotech Showcase 2019
|Date:||Monday, January 7, 2019|
|Time:||10:00 a.m. Pacific Standard Time|
|Location:||Hilton San Francisco Union Square, San Francisco, CA|
|Track:||Franciscan A, (Ballroom Level)|
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.plxpharma.com under the News & Events section.
Vazalore 325 mg is an FDA-approved aspirin product being developed to provide high-risk cardiovascular and stroke patients with more reliable and predictable antiplatelet efficacy as compared to enteric-coated aspirin, while also reducing the adverse gastric events common in an acute setting. PLx is focused on manufacturing, scale-up and label finalization for Vazalore 325 mg aspirin dosage form and preparing an sNDA for Vazalore 81 mg maintenance dose form.
About PLx Pharma Inc.
To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.
Source: PLx Pharma Inc.